---
layout: default
title: Cetrorelix
parent: Model Prediction Only (L5)
nav_order: 176
evidence_level: L5
indication_count: 10
---

# Cetrorelix
{: .fs-9 }

Evidence Level: **L5** | Predicted Indications: **10** 
{: .fs-6 .fw-300 }

---

## Table of Contents
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## Pharmacist Assessment Report

</div>

# Cetrorelix: From Controlled Ovarian Stimulation to Hypertrichosis

## One-Sentence Summary

Cetrorelix is a GnRH receptor antagonist, marketed in Canada as Cetrotide and used to prevent premature LH surges during fertility treatment.
The TxGNN model predicts it may be effective for **Hypertrichosis**, but **no clinical trials and no publications** support this pair.
The score is a graph-based prediction only, and no plausible mechanistic link has been identified.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Inhibition of premature LH surges in controlled ovarian stimulation (general product knowledge; the Canadian license record does not state an indication) |
| Predicted New Indication | Hypertrichosis |
| TxGNN Prediction Score | 99.98% |
| Evidence Level | L5 (model prediction only) |
| Canada Market Status | ✓ Marketed |
| Number of DINs | 1 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Cetrorelix blocks the pituitary GnRH receptor. This suppresses LH and FSH release and lowers gonadal steroids. Detailed mechanism data are not in the evidence record, but this is the known class effect.

Hypertrichosis is excessive hair growth that is not driven by the GnRH-gonadal axis. The analysis found **no plausible mechanistic link** between GnRH antagonism and this condition. The very high TxGNN score (99.98%, rank 893) most likely reflects graph proximity in the knowledge graph, not pharmacological rationale. No trial or publication supports it.

The other top-ranked predictions are also weak. They include Ambras-type hypertrichosis, hair shaft abnormalities, Dandy-Walker syndromes and persistent fetal circulation. The only biologically plausible candidate in the list is **central precocious puberty** (rank 10). Its mechanism is a direct GnRH axis target, but it also has no supporting clinical evidence yet.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## Canada Market Information

| DIN | Product Name | Dosage Form | Approved Indication |
|---------|------|------|-----------|
| 2247766 | CETROTIDE | Not recorded | Not recorded |

---

## Safety Considerations

Please refer to the package insert for safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The prediction is supported only by a model score. There is no trial or literature evidence, and there is no mechanistic reason to expect GnRH antagonism to affect hypertrichosis. It should not advance.

**To proceed, the following is needed:**
- A credible mechanistic hypothesis linking GnRH antagonism to hypertrichosis; without one, the pair should be deprioritised
- Health Canada product monograph data (indication, warnings, contraindications, dosage form)
- Mechanism of action data from DrugBank
- A separate evidence review of **central precocious puberty**, the most biologically plausible candidate. It would need to address pediatric dosing, safety and formulation (short-acting injectable).

*This report is for research reference only and does not constitute medical advice. Repurposing candidates require clinical validation before any use.*
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

